EOS imaging Achieves Its 100th Installation in the United States
August 21 2018 - 12:27PM
Business Wire
Methodist Dallas Medical Center represents the
10th installation in Texas
Milestones reflect growing adoption of EOS
technology as a standard of care in orthopedics
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI -
Eligible PEA - PME), the pioneer of 2D/3D imaging and data
solutions for orthopedics, today announced that the Methodist
Dallas Medical Center installed an EOS® system for low-dose, 2D/3D
imaging of adult and pediatric patients. The installation
marks the 100th system installed in the United States and the 10th
system in Texas.
Methodist Dallas Medical Center is part of the Methodist Health
System that operates 10 hospitals in Texas and more than two dozen
Methodist Family Health Centers and Medical Groups. The Methodist
Dallas Medical Center has developed a comprehensive Neurological
and Spine program with surgical staff specializing in back pain,
tumors, stroke conditions, spinal disorders and injuries as well as
other neurological conditions.
“Achieving the 100th EOS® installation in the U.S. and 10th in
the state of Texas represent great milestones for our Company that
reflect the adoption of the EOS technology as a standard of care in
all orthopedic points of care, including the large and high growth
community hospitals and private practices market,” said Marie
Meynadier, CEO. “Addressing the needs of these care providers in
the U.S. has been an important part of our commercial strategy in
the last year, and we are happy to see that our investments are
prompting an acceleration of the EOS® adoption. Our dynamics in the
U.S., our largest and fastest growing market, have reached an
excellent pace and together with our momentum in all markets
provide confidence in our growth.”
About EOS imaging
EOS imaging designs, develops and markets EOS®, a major
innovative medical imaging solution dedicated to osteo-articular
pathologies and orthopedics combining equipment and services and
targeting a $2B per year market opportunity. EOS imaging is
currently present in 31 countries, including the United States
under FDA agreement, Japan, China and the European Union under CE
labelling, through the over 250 installed EOS® platforms
representing around one million patient exams every year. Revenues
were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017.
For more information, please visit www.eos-imaging.com.
EOS imaging has been selected to integrate the EnterNext ©
PEA - PME 150 index, composed of 150 French, listed companies on
the Euronext markets in Paris.
EOS imaging is listed on Compartment C of Euronext ParisISIN:
FR0011191766 - Ticker: EOSI
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180821005549/en/
EOS imagingMarie MeynadierCEOPh: +33 (0)1 55 25 60
60investors@eos-imaging.comorPress Relations (US)Kirsten
ThomasThe Ruth GroupPh:
508-280-6592kthomas@theruthgroup.comorInvestor Relations
(US)Matt Picciano / Emma PoalilloThe Ruth GroupPh: 646-536-7008
/ 7024EOS-imagingIR@theruthgroup.com